lawsuit

The case, which was originally being fought between Enzo and Hologic, was decided in favor of Becton Dickinson, Hologic's co-plaintiff.

In addition to the $24 million jury verdict, 10x must pay an additional $8.3 million in damages and $2.2 million in interest. It has appealed the case.

Among the claims, NeuMoDx has alleged that BD was kept up to date on the firm's technology as it was developed and that one of the patents was duplicitously expanded by BD.

The Broad Institute called UC's new legal strategy "deeply unfortunate" and called on the university to "move beyond litigation."

A federal judge upheld a $24 million jury award to Bio-Rad, while a trade court judge said Bio-Rad imported microfluidics that infringed 10x patents.

Guardant told a federal judge that it believes Foundation Medicine and Personal Genome Diagnostics are coordinating to invalidate its patents.

The company's patent related to labeled nucleotides for use as diagnostic tools and as therapeutic agents has been invalidated.

The complaint alleges that NeuMoDx is willfully infringing on six BD-held patents, and demands injunctive relief, damages, and a jury trial.

A UK court determined that Ariosa's licensee infringed upon at least one claim of Illumina's European patent 1 524 321 and upheld the patent's validity.